HDAC4 (histone deacetylase 4; HGNC:14063, NCBI Gene ID 9759) is a human locus mapped to chromosome band 2q37.3 that encodes class IIa signal-responsive pseudo-deacetylase / NCoR-HDAC3 scaffold HDAC4 (1,084 aa; 119 kDa). HDAC4 acts in activity-dependent CaMKII/PKD/SIK phosphorylation & 14-3-3 cytoplasmic export -> derepression of MEF2 & RUNX2 in muscle, heart, bone & neurons, together with HDAC5 (Synergistic Class IIa Paralog in Heart & Muscle), HDAC3 (Catalytic Deacetylase Recruited by Nuclear HDAC4), and MYOG (Myogenin Regulated by HDAC4 Upon Denervation). Encodes the signal-responsive Class IIa histone deacetylase 4 that shuttles between nucleus and cytoplasm to couple calcium and cAMP signaling to MEF2 and RUNX2 transcription.
Activity-dependent CaMKII/PKD/SIK phosphorylation & 14-3-3 cytoplasmic export -> derepression of MEF2 & RUNX2 in muscle, heart, bone & neurons
Clinical / Therapeutic Role
Haploinsufficiency/C-terminal truncations at 2q37.3 cause Brachydactyly-Mental Retardation syndrome; targeted by tasquinimod & SIK activators
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 27-exon gene spanning ~353 kb at the subtelomeric tip of chromosome 2q37.3, encoding a large 1,084-amino-acid bipartite protein: an extended N-terminal regulatory domain containing a MEF2-binding amphipathic helix, a glutamine-rich coil, and three conserved Serine residues (Ser246, Ser467, Ser632) flanked by 14-3-3 binding motifs, plus a C-terminal zinc-binding domain in which the catalytic tyrosine of Class I HDACs is evolutionary replaced by a Histidine (His976)—giving vertebrate Class IIa HDACs negligible intrinsic deacetylase activity on acetyl-lysine and making them signal-responsive scaffolds that recruit catalytic NCoR1/SMRT-HDAC3.
Biochemical & Physiological Mechanism: Acts as a calcium- and hormone-sensitive molecular switch: in quiescent or denervated cells, unphosphorylated HDAC4 resides in the nucleus bound to MEF2, RUNX2, and SRF transcription factors while recruiting NCoR1-HDAC3 to silence slow-oxidative myofiber genes, cardiac hypertrophy genes, and chondrocyte hypertrophy; when neuromuscular electrical activity activates CaMKII/PKD (or when parathyroid hormone activates PKA to inhibit salt-inducible kinases), phosphorylated Ser246/467/632 bind 14-3-3 chaperones that export HDAC4 into the cytoplasm, immediately unleashing MEF2-PGC-1alpha (PPARGC1A) oxidative remodeling or RUNX2 osteogenesis.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Terminal 2q37.3 microdeletions or heterozygous loss-of-function mutations in HDAC4 cause Brachydactyly-Mental Retardation syndrome (BDMR), whereas de novo gain-of-function missense variants in the 14-3-3 binding sites (preventing cytoplasmic export so HDAC4 remains constitutively nuclear) cause Wakeling neurodevelopmental and skeletal syndrome; in motor neuron diseases (ALS, SMA) and denervation, nuclear HDAC4 accumulation drives DACHSUND-myogenin (MYOG) re-induction.
Therapeutic & Clinical Pharmacology: Pharmacological stabilization of cytoplasmic HDAC4 or disruption of the HDAC4-NCoR-HDAC3 complex (such as with tasquinimod or Class IIa-selective trifluoromethyloxadiazole inhibitors TMP195/TMP269) is investigated in Duchenne muscular dystrophy, heart failure, and Huntington disease.